Biblio

Export 7 results:
Author Title [ Type(Asc)] Year
Filters: Author is Brashear, H Robert  [Clear All Filters]
Journal Article
S. Salloway, Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., Reichert, M., Ketter, N., Nejadnik, B., Guenzler, V., Miloslavsky, M., Wang, D., Lu, Y., Lull, J., Tudor, I. Cristina, Liu, E., Grundman, M., Yuen, E., Black, R., and H Brashear, R., “Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.”, N Engl J Med, vol. 370, no. 4, pp. 322-33, 2014.
M. Brody, Liu, E., Di, J., Lu, M., Margolin, R. A., Werth, J. L., Booth, K., Shadman, A., H Brashear, R., and Novak, G., “A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Safety, Pharmacokinetics, and Biomarker Results of Subcutaneous Bapineuzumab in Patients with mild to moderate Alzheimer's disease.”, J Alzheimers Dis, vol. 54, no. 4, pp. 1509-1519, 2016.
S. P. Salloway, Sperling, R., Fox, N. C., Sabbagh, M. N., Honig, L. S., Porsteinsson, A. P., Rofael, H., Ketter, N., Wang, D., Liu, E., Carr, S., Black, R. S., and H Brashear, R., “Long-Term Follow Up of Patients with Mild-to-Moderate Alzheimer's Disease Treated with Bapineuzumab in a Phase III, Open-Label, Extension Study.”, J Alzheimers Dis, vol. 64, no. 3, pp. 689-707, 2018.
R. H Brashear, Ketter, N., Bogert, J., Di, J., Salloway, S. P., and Sperling, R., “Clinical Evaluation of Amyloid-Related Imaging Abnormalities in Bapineuzumab Phase III Studies.”, J Alzheimers Dis, vol. 66, no. 4, pp. 1409-1424, 2018.
G. Novak, Fox, N., Clegg, S., Nielsen, C., Einstein, S., Lu, Y., Tudor, I. Cristina, Gregg, K., Di, J., Collins, P., Wyman, B. T., Yuen, E., Grundman, M., H Brashear, R., and Liu, E., “Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer's Disease.”, J Alzheimers Dis, vol. 49, no. 4, pp. 1123-34, 2016.
N. Ketter, H Brashear, R., Bogert, J., Di, J., Miaux, Y., Gass, A., Purcell, D. D., Barkhof, F., and H Arrighi, M., “Central Review of Amyloid-Related Imaging Abnormalities in Two Phase III Clinical Trials of Bapineuzumab in Mild-To-Moderate Alzheimer's Disease Patients.”, J Alzheimers Dis, vol. 57, no. 2, pp. 557-573, 2017.
A. Russu, Samtani, M. N., Xu, S., Adedokun, O. J., Lu, M., Ito, K., Corrigan, B., Raje, S., Liu, E., H Brashear, R., Styren, S., and Hu, C., “Biomarker Exposure-Response Analysis in Mild-To-Moderate Alzheimer's Disease Trials of Bapineuzumab.”, J Alzheimers Dis, vol. 53, no. 2, pp. 535-46, 2016.